Prognostic Significance and Longitudinal Assessment of Patient-reported Quality of Life and Symptoms in High-risk Myelodysplastic Syndromes. A Large-scale International Study.
- To investigate the prognostic value of pre-treatment patient-reported fatigue in
relation to overall survival of patients with newly diagnosed intermediate-2 or
high-risk myelodysplastic syndromes according to the International Prognostic Scoring
- To prospectively evaluate short-term quality of life (QOL) and symptoms.
- To establish international baseline QOL and symptom reference data to be used as
benchmarks for comparisons in future studies.
- To investigate the prognostic value of early changes in QOL and symptoms (from baseline
to week 4) in relation to acute myeloid leukemia (AML) transformation and overall
- To investigate the prognostic value of various baseline patient-reported QOL and
symptoms in relation to AML transformation and overall survival.
- To devise a prognostic patient-based index.
- To assess patient preferences for involvement in treatment decision-making and the
relationship between patient preferences and patient characteristics.
- To compare patient preferences for involvement in treatment decision-making with the
perceptions of their treating physicians.
OUTLINE: This is a multicenter study.
Patients complete EORTC QLQ-C30, FACIT-Fatigue Scale, and Control Preference Scale
questionnaires at baseline, 4 weeks, and 8 weeks.
Observational Model: Cohort, Time Perspective: Prospective
Prognostic value of pre-treatment fatigue in relation to overall survival
Fabio Efficace, PhD
Gruppo Italiano Malattie EMatologiche dell'Adulto
Italy: Ethics Committee
|University of Chicago||Chicago, Illinois 60637|
|The University of Texas, MD Anderson Cancer Center||Houston, Texas 77030|
|University of Southern California (USC)||Los Angeles, California 90007|
|Memorial Sloan-Kettering Cancer Center (MSKCC)||New York, New York 10065|